☆ 4.4 Editorial Material

The doctor's dilemma: Challenges in the diagnosis and care of homozygous familial hypercholesterolemia

JOURNAL OF CLINICAL LIPIDOLOGY (2014)

Journal

JOURNAL OF CLINICAL LIPIDOLOGY

Volume 8, Issue 6, Pages 542-549

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jacl.2014.09.005

Keywords

-

Categories

Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Marked plaque regression in homozygous familial hypercholesterolemia

Laurens F. Reeskamp, Nick S. Nurmohamed, Michiel J. Bom, R. Nils Planken, Roel S. Driessen, Pepijn A. van Diemen, Ilse K. Luirink, Jaap W. Groothoff, Irene M. Kuipers, Paul Knaapen, Erik S. G. Stroes, Albert Wiegman, G. Kees Hovingh

Summary: This study assessed the effectiveness of intensive lipid-lowering therapy in two adolescent patients with homozygous familial hypercholesterolemia (HoFH) through coronary computed tomography angiography (CCTA). The results showed a significant reduction in atherosclerotic plaque volume after 6 months of treatment, indicating the potential for plaque regression in young HoFH patients.

ATHEROSCLEROSIS (2021)

Add to Collection

Review Chemistry, Medicinal

Current Treatment Options in Homozygous Familial Hypercholesterolemia

Meral Kayikcioglu, Lale Tokgozoglu

Summary: HoFH is a rare form of familial hypercholesterolemia that causes extremely high levels of LDL-C, leading to early onset of ASCVD if left untreated. Most individuals with HoFH are resistant to conventional lipid lowering therapy due to absent or defective LDL-receptor activity. New agents that provide LDL-receptor independent cholesterol reduction offer promising pharmacotherapies for HoFH patients.

PHARMACEUTICALS (2023)

Add to Collection

Review Peripheral Vascular Disease

Advancements in the Treatment of Homozygous Familial Hypercholesterolemia

Archna Bajaj, Marina Cuchel

Summary: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by extreme elevations of low-density lipoprotein cholesterol (LDL-C), requiring aggressive treatment to prevent premature atherosclerotic cardiovascular disease (ASCVD). The treatment landscape for HoFH has rapidly progressed over the last decade, with the addition of several new therapy options such as PCSK9 inhibitors, lomitapide, and ANGPTL3 inhibitors. Lipoprotein apheresis and gene therapy may also be necessary for some patients.

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment

Natalie Arnold, Wolfgang Koenig

Summary: Familial hypercholesterolemia is a condition characterized by elevated LDL concentrations from birth, but it is often underdiagnosed and undertreated. Undiagnosed and undertreated FH leads to accelerated atherosclerotic cardiovascular disease. Despite the introduction of new treatment modalities, many patients still struggle to achieve the recommended LDL cholesterol target levels.

REVIEWS IN CARDIOVASCULAR MEDICINE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Quality of life and coping in Dutch homozygous familial hypercholesterolemia patients: A qualitative study

W. C. M. Janneke Mulder, W. Leonieke Kranenburg, J. Willemijn Treling, G. Kees Hovingh, H. W. Joost Rutten, J. Jan Busschbach, E. Jeanine Roeters van Lennep

Summary: This study investigates how Dutch patients experience and cope with Homozygous familial hypercholesterolemia (HoFH) in daily life. The study found that Dutch HoFH patients use a variety of effective coping mechanisms, resulting in only a slight impact on their subjective quality of life.

ATHEROSCLEROSIS (2022)

Add to Collection

Review Peripheral Vascular Disease

Homozygous Familial Hypercholesterolemia

Atsushi Nohara, Hayato Tada, Masatsune Ogura, Sachiko Okazaki, Koh Ono, Hitoshi Shimano, Hiroyuki Daida, Kazushige Dobashi, Toshio Hayashi, Mika Hori, Kota Matsuki, Tetsuo Minamino, Shinji Yokoyama, Mariko Harada-Shiba

Summary: Familial hypercholesterolemia (FH) is a genetic disorder with increasing prevalence of HoFH, leading to cardiovascular complications. Treatment involves lipid-lowering therapy and combination drug therapies to manage the condition.

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Evolocumab in patients with homozygous familial hypercholesterolemia in India

Sandeep Bansal, Andrea Ruzza, Jps Sawhney, Govind Kulkarni, Shammana Iyengar, Vimal Mehta, Andrew Hamer, You Wu, Frederick J. Raal

Summary: The RAMAN study evaluated the safety and tolerability of evolocumab in patients with HoFH in India, showing that the drug was safe and well tolerated in this population with smaller reductions in LDL-C and other lipids than previous studies.

JOURNAL OF CLINICAL LIPIDOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

Improving Familial Hypercholesterolemia Diagnosis Using an EMR-based Hybrid Diagnostic Model

Wael E. Eid, Emma Hatfield Sapp, Abby Wendt, Amity Lumpp, Carl Miller

Summary: Familial hypercholesterolemia (FH) is underdiagnosed and undertreated in primary care populations. A study using a hybrid model and electronic medical record data accurately identified FH patients and found a higher prevalence of coronary artery disease in these patients. The use of statin and other lipid-lowering therapies was suboptimal.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Add to Collection

Review Biochemistry & Molecular Biology

New algorithms for treating homozygous familial hypercholesterolemia

Tycho R. Tromp, Marina Cuchel

Summary: Lowering LDL-C levels to normal in patients with HoFH is challenging, but a combination of multiple lipid-lowering therapies is key. Therapies acting independently of the LDL receptor pathway, such as lomitapide and evinacumab, are considered game changers for many patients with HoFH.

CURRENT OPINION IN LIPIDOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry

Marina Cuchel, Paul C. Lee, Lisa C. Hudgins, P. Barton Duell, Zahid Ahmad, Seth J. Baum, MacRae F. Linton, Sarah D. de Ferranti, Christie M. Ballantyne, John A. Larry, Linda C. Hemphill, Iris Kindt, Samuel S. Gidding, Seth S. Martin, Patrick M. Moriarty, Paul P. Thompson, James A. Underberg, John R. Guyton, Rolf L. Andersen, David J. Whellan, Irwin Benuck, John P. Kane, Kelly Myers, William Howard, David Staszak, Allison Jamison, Mary C. Card, Mafalda Bourbon, Joana R. Chora, Daniel J. Rader, Joshua W. Knowles, Katherine Wilemon, Mary P. McGowan

Summary: This study investigated the diagnosis and treatment of HoFH in the United States and found a low diagnosis rate and low treatment rate, highlighting the need for enhanced screening and treatment to reduce the burden of the disease.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Add to Collection

Article Medical Laboratory Technology

Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype

Ana M. Bea, Ana Cenarro, Victoria Marco-Benedi, Martin Laclaustra, Cesar Martin, Daiana Ibarretxe, Xavier Pinto, Teresa Arrobas, Clara Vinals, Fernando Civeira, Salvador Olmos

Summary: This study aimed to define the characteristics of dysbetalipoproteinemia (DBL) based on APOE analysis and propose a screening algorithm for familial dysbetalipoproteinemia (FDBL). The combination of non-HDLc/apoB>=1.7 and triglycerides/apoB>=1.35 showed the best diagnostic performance for identifying subjects with hyperlipidemia and APOE2/2 genotype.

CLINICAL CHEMISTRY (2023)

Add to Collection

Review Pharmacology & Pharmacy

Health-related quality of life in homozygous familial hypercholesterolemia: A systematic review and meta-analysis

Latifah Alothman, Alexandre M. Belanger, Isabelle Ruel, Liam R. Brunham, Lindsay Hales, Jacques Genest, Leo E. Akioyamen

Summary: This systematic review examined the association between Homozygous familial hypercholesterolemia (HoFH) and health-related quality of life (HRQL). The findings suggest that HoFH patients have lower HRQL compared to the general population, particularly in the areas of physical functioning, social functioning, and general health. The review also highlights the high treatment burden and lack of psychological support for patients. However, there is a lack of studies evaluating the association of HoFH with mental health outcomes.

JOURNAL OF CLINICAL LIPIDOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Evinacumab for the treatment of homozygous familial hypercholesterolemia

Yanli Gao, Baoqi Zhang, Junyi Yang

Summary: This review examines the pharmacological characteristics, clinical evidence, and safety of evinacumab, an ANGPTL3 inhibitor. Phase 3 clinical trials showed that evinacumab can significantly reduce LDL-C levels in patients with HoFH, making it a potential valuable treatment option.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia

Zhiyong Du, Fan Li, Long Jiang, Linyi Li, Yunhui Du, Huahui Yu, Yan Luo, Yu Wang, Haili Sun, Chaowei Hu, Jianping Li, Ya Yang, Xiaolu Jiao, Luya Wang, Yanwen Qin

Summary: This study comprehensively characterizes the metabolic features and risk factors of homozygous familial hypercholesterolemia (HoFH) using metabolic systems strategies. The study findings suggest that besides LDL-C, various bioactive metabolites in multiple pathways may contribute to cardiovascular complications in HoFH patients. Additionally, a small panel of metabolites was identified as potential predictors of cardiovascular events in HoFH patients.

BMC MEDICINE (2023)

Add to Collection

Article Computer Science, Information Systems

Doctor's Dilemma: Evaluating an Explainable Subtractive Spatial Lightweight Convolutional Neural Network for Brain Tumor Diagnosis

Ambeshwar Kumar, Ramachandran Manikandan, Utku Kose, Deepak Gupta, Suresh C. Satapathy

Summary: In the field of medicine, explainable research on using deep learning for medical image analysis is a hot topic. Research shows that the Subtractive Spatial Lightweight Convolutional Neural Network (SSLW-CNN) model has good performance in brain tumor classification.

ACM TRANSACTIONS ON MULTIMEDIA COMPUTING COMMUNICATIONS AND APPLICATIONS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Jean-Claude Tardif, Ewa Karwatowska-Prokopczuk, Eric St Amour, Christie M. Ballantyne, Michael D. Shapiro, Patrick M. Moriarty, Seth J. Baum, Eunju Hurh, Victoria J. Bartlett, Joyce Kingsbury, Amparo L. Figueroa, Veronica J. Alexander, Joseph Tami, Joseph L. Witztum, Richard S. Geary, Louis St L. O'Dea, Sotirios Tsimikas, Daniel Gaudet

Summary: This clinical trial evaluated the efficacy of Olezarsen in reducing triglyceride levels in patients with hypertriglyceridemia. The results showed that Olezarsen significantly reduced triglyceride levels and had positive effects on lipoprotein and cholesterol levels. This drug may have important clinical applications in the treatment of hypertriglyceridemia and cardiovascular disease.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

Michael J. Koren, Patrick Maurice Moriarty, Seth J. Baum, Joel Neutel, Martha Hernandez-Illas, Howard S. Weintraub, Monica Florio, Helina Kassahun, Stacey Melquist, Tracy Varrieur, Saptarsi M. Haldar, Winnie Sohn, Huei Wang, Mary Elliott-Davey, Brooke M. Rock, Tao Pei, Oliver Homann, Jennifer Hellawell, Gerald F. Watts

Summary: This study reports the discovery and development of a new drug, olpasiran, which can directly inhibit the translation of Lp(a) messenger RNA, leading to a significant reduction in plasma Lp(a) concentration. In animal and human trials, olpasiran demonstrated good safety and tolerability, and maintained a sustained reduction in high plasma Lp(a) concentration.

NATURE MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification

Yannick Kaiser, Janine E. van der Toorn, Sunny S. Singh, Kang H. Zheng, Maryam Kavousi, Eric J. G. Sijbrands, Erik S. G. Stroes, Meike W. Vernooij, Yolanda B. de Rijke, S. Matthijs Boekholdt, Daniel Bos

Summary: The study aims to evaluate the relationship between Lp(a) and the occurrence and progression of aortic valve calcium (AVC). The results indicate that high serum levels of Lp(a) are associated with baseline and new-onset AVC, but not with AVC progression.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Article Medicine, General & Internal

Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population

Navin Suthahar, Kan Wang, Victor W. Zwartkruis, Stephan J. L. Bakker, Silvio E. Inzucchi, Tim R. Eijgenraam, Fariba Ahmadizar, Eric G. Sijbrands, Ron T. Gansevoort, Lyanne M. Kieneker, Dirk J. van Veldhuisen, Maryam Kavousi, Rudolf A. de Boer

Summary: Relative fat mass (RFM), a novel anthropometric equation based on height and waist measurements, is strongly associated with incident type-2 diabetes (T2D) and shows potential as a predictor of future diabetes risk in the general population, outperforming BMI, waist circumference, and waist-to-hip ratio.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2023)

Add to Collection

Article Biology

Mortality in Pedigrees with Acute Intermittent Porphyria

Rochus Neeleman, Kyra Musters, Margreet Wagenmakers, Sophie Mijnhout, Edith Friesema, Eric Sijbrands, Janneke Langendonk

Summary: This study estimates the all-cause mortality in pedigrees with HMBS gene variants that cause acute intermittent porphyria (AIP). The overall mortality was found to be similar to the general Dutch population, but there was excess mortality in certain age groups of women and men.

LIFE-BASEL (2022)

Add to Collection

Article Geriatrics & Gerontology

Associations of baseline glycemic status and its transitions with cognitive and physical functioning decline

Kan Wang, Hui Gao, Eric J. G. Sijbrands, Maryam Kavousi, Fariba Ahmadizar

Summary: The impact of glycemic impairment (normoglycemia, prediabetes and diabetes) on cognition and physical function is inconsistent. This population-based cohort study found that baseline diabetes was associated with a faster decline in orientation and an increase in physical function score. No effect of prediabetes on cognition and physical function was observed.

MATURITAS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

Robert S. Rosenson, Daniel Gaudet, Christie M. Ballantyne, Seth J. Baum, Jean Bergeron, Erin E. Kershaw, Patrick M. Moriarty, Paolo Rubba, David C. Whitcomb, Poulabi Banerjee, Andrew Gewitz, Claudia Gonzaga-Jauregui, Jennifer McGinniss, Manish P. Ponda, Robert Pordy, Jian Zhao, Daniel J. Rader

Summary: Severe hypertriglyceridemia (sHTG) is a known risk factor for acute pancreatitis. Current therapies for sHTG are often insufficient, and this phase 2 trial evaluated the use of evinacumab in patients with sHTG. Although evinacumab showed some effectiveness in reducing triglyceride levels, it did not meet the primary endpoint. However, the safety profile and lipid changes observed support further evaluation in larger trials.

NATURE MEDICINE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Lipoprotein(a) is associated with a larger systemic burden of arterial calcification

Sunny S. Singh, Janine E. van der Toorn, Eric J. G. Sijbrands, Yolanda B. de Rijke, Maryam Kavousi, Daniel Bos

Summary: This study aimed to investigate the association between Lp(a) and arteriosclerosis. The results showed that higher levels of Lp(a) were consistently associated with increased calcification volumes in multiple arteries, including coronary arteries, aortic arch, and carotid arteries. The findings suggest that Lp(a) is a systemic risk factor for arteriosclerosis, highlighting its potential as a target for treatment.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2023)

Add to Collection

Article Multidisciplinary Sciences

A guide to sharing open healthcare data under the General Data Protection Regulation

Jip W. T. M. de Kok, Miguel a. Armengol de la Hoz, Ymke de Jong, Veronique Brokke, Paul W. G. Elbers, Patrick Thoral, Alejandro M. Castillejo, Tomas E. Trenor, Jose M. Castellano, Alberto Bronchalo, Tobias Merz, Martin Faltys, Cristina Casares, Araceli Jimenez, Jaime Requejo, Sonia Gutierrez, David Curto, Gunnar M. Raetsch, Jan H. Peppink, Ronald Driessen, Eric J. G. Sijbrands, Erwin J. O. Kompanje, Armand R. J. Girbes, Jose Barberan, Jose Felipe Varona, Paula Villares, Iwan C. C. van der Horst, Minnan Xu, Leo Anthony Celi, Bas C. T. van Bussel, Xavier Borrat

Summary: Sharing healthcare data is crucial for enhancing patient care at the ICU, but it is challenging due to EU privacy regulations. To address this, we studied four successful open ICU healthcare databases to explore appropriate ways of sharing healthcare data in the EU. Through a questionnaire and discussions with experts, we identified four approaches and formulated seven recommendations for open healthcare data sharing, considering data security, ease of use, sustainability, and implementability.

SCIENTIFIC DATA (2023)

Add to Collection

Article Endocrinology & Metabolism

Four missense genetic variants in CUBN are associated with higher levels of eGFR in non-diabetes but not in diabetes mellitus or its subtypes: A genetic association study in Europeans

Nicoline Uglebjerg, Fariba Ahmadizar, Dina M. Aly, Marisa Canadas-Garre, Claire Hill, Annemieke Naber, Asmundur Oddsson, Sunny S. Singh, Laura Smyth, David-Alexandre Tregouet, Layal Chaker, Mohsen Ghanbari, Valgerdur Steinthorsdottir, Emma Ahlqvist, Samy Hadjadj, Mandy Van Hoek, Maryam Kavousi, Amy Jayne McKnight, Eric J. Sijbrands, Kari Stefansson, Matias Simons, Peter Rossing, Tarunveer S. Ahluwalia

Summary: This study aims to explore the association between four missense variants in the CUBN gene and estimated glomerular filtration rate (eGFR) and investigate their effects on kidney-related traits. The results show significant positive associations between these variants and eGFR in individuals without diabetes.

FRONTIERS IN ENDOCRINOLOGY (2023)

Add to Collection

Article Hematology

Subtyping Severe Hypercholesterolemia by Genetic Determinant to Stratify Risk of Coronary Artery Disease

Alexander S. F. Berry, Laney K. Jones, Eric J. Sijbrands, Samuel S. Gidding, Matthew T. Oetjens

Summary: This study found that genetic subtyping based on monogenic familial hypercholesterolemia and Lp(a) provides better stratification of 10-year incident CAD risk than LDL-C-based stratification in individuals with severe hypercholesterolemia.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Identifying lipid traces of atherogenic mechanisms in human carotid plaque

Nuria Slijkhuis, Mark Towers, Mina Mirzaian, Suze-Anne Korteland, Bram Heijs, Kim van Gaalen, Ingeborg Nieuwenhuizen, Alex Nigg, Kim van der Heiden, Yolanda B. van der Rijke, Aad van der Lugt, Eric J. G. Sijbrands, Emmanuelle Claude, Gijs van Soest

Summary: This study used lipidomics and mass spectrometry imaging to investigate lipid signatures in advanced human carotid plaque and plasma samples. By comparing lipid species in plaque and plasma, the study identified specific lipid species that were associated with destabilization processes in plaque.

ATHEROSCLEROSIS (2023)

Add to Collection

Article Endocrinology & Metabolism

IgG N-glycans are associated with prevalent and incident complications of type 2 diabetes

Elham Memarian, Ralph Heijmans, Roderick C. Slieker, Adriana Sierra, Olga Gornik, Joline W. J. Beulens, Maja Hanic, Petra Elders, Julio Pascual, Eric Sijbrands, Gordan Lauc, Viktoria Dotz, Clara Barrios, Leen M. 't Hart, Manfred Wuhrer, Mandy van Hoek

Summary: Inflammation plays an important role in the development of type 2 diabetes complications, and the N-glycosylation of IgG affects its role in inflammation. This study found that IgG N-glycosylation, particularly galactosylation and to a lesser extent sialylation, is associated with a higher prevalence and future development of macro- and microvascular complications of diabetes.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids

Annemieke Naber, Daniel Demus, Roderick Slieker, Simone Nicolardi, Joline W. J. Beulens, Petra J. M. Elders, Aloysius G. Lieverse, Eric J. G. Sijbrands, Leen M. 't Hart, Manfred Wuhrer, Mandy van Hoek

Summary: This study aimed to investigate the impact of apo-CIII glycosylation on lipid traits and type 2 diabetes prevalence. The researchers conducted a GWAS on different apo-CIII proteoforms and identified genetic loci associated with glycosylation and its relation to lipids and diabetes. The study confirmed the significant role of GALNT2 gene in apo-CIII O-glycosylation and its association with lipid parameters. Additionally, the IFT172/NRBP1 region was found to be involved in apo-CIII sialylation and hypertriglyceridemia.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Neurosciences

Sphingolipids in Cerebrospinal Fluid and Plasma Lipoproteins of APOE4 Homozygotes and Non-APOE4 Carriers with Mild Cognitive Impairment versus Subjective Cognitive Decline

Sandra den Hoedt, Kristien Y. Dorst-Lagerwerf, Helga E. de Vries, Annemieke J. M. Rozemuller, Philip Scheltens, Jochen Walter, Eric J. G. Sijbrands, Pilar Martinez-Martinez, Adrie J. M. Verhoeven, Charlotte E. Teunissen, Monique T. Mulder

Summary: Alzheimer's disease (AD) patients show changes in cerebrospinal fluid (CSF) and plasma sphingolipids. The APOE4 genotype affects common sphingolipids in CSF and plasma of patients with early stages of AD.

JOURNAL OF ALZHEIMERS DISEASE REPORTS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.